Arcus Biosciences RCUS Investments - Amortized Cost Basis
Investments - Amortized Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's investments - amortized cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Arcus Biosciences's investments - amortized cost basis?
- Arcus Biosciences (RCUS) reported investments - amortized cost basis of $877M in Q1 2026.
- How has Arcus Biosciences's investments - amortized cost basis changed year-over-year?
- Arcus Biosciences's investments - amortized cost basis decreased by 12.7% year-over-year, from $1.01B to $877M.
- What is the long-term trend for Arcus Biosciences's investments - amortized cost basis?
- Over 3 years (2022 to 2025), Arcus Biosciences's investments - amortized cost basis has grown at a -4.1% compound annual growth rate (CAGR), from $1.15B to $1.01B.